Yong, Kwee

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 827

Multiple myeloma: patient outcomes in real‐world practice

Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 326

Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression

Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 187

Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+ CD45RA+ CD27− T cells: the potential involvement of interleukin-7 in this process: IL-7 induces re-expression of CD45RA in CD4+ T cells

Libri, V., Azevedo, R. I., Jackson, S. E., Di Mitri, D., Lachmann, R., Fuhrmann, S., Vukmanovic-Stejic, M., Yong, K., Battistini, L., Kern, F., et al. (2011) · Immunology

Cytomegalovirus and herpesvirus researchT-cell and B-cell Immunology

Cited by 111

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

Cowan, A., Ferrari, F., Freeman, S. S., Redd, R., El-Khoury, H., Perry, J., Patel, V., Kaur, P., Barr, H., Lee, D. J., et al. (2023) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 86

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Bustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 35

Genomic landscape of multiple myeloma and its precursor conditions

Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 32

VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

Moreau, P., Dimopoulos, M. A. C., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Casca, F., Mace, S., et al. (2022) · Annals of Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE

Dhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., et al. (2022) · HemaSphere

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 9

P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database

Dhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., et al. (2022) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3